Time is running out! Just 2 weeks left in our WeFunder campaign. 

For too long, patients with Acute Myeloid Leukemia (AML), Hodgkin’s Lymphoma, Parkinson’s, and ARDS have had to endure treatments, if any exist, that do more harm than good, treatments with lifelong complications.

PhorMed’s platform drug, RP-323, is different:

✅ It doesn’t just treat symptoms, it repairs damaged cells and targets disease at its core.

✅ In early studies, 83% of AML patients saw remission.

🧪 We are advancing 3 clinical trials for AML, Hodgkin’s Lymphoma and ARDS.

📈 $53M valuation today with remarkable growth potential: Targeting billion-dollar markets with no real competition.

Our technology is designed to treat diseases where current options fall short.

Every dollar invested helps drive our work forward. Help save lives and join us before it’s too late!